Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) has been studied as a biomarker of major depressive disorder (MDD). Besides diagnostic biomarkers, clinically useful biomarkers can inform response to treatment. We aimed to review all studies that sought to relate BDNF baseline levels, or BDNF polymorphisms, with response to treatment in MDD. In order to achieve this, we performed a systematic review of studies that explored the relation of BDNF with both pharmacological and non-pharmacological treatment. Finally, we reviewed the evidence that relates peripheral levels of BDNF and BDNF polymorphisms with the development and management of treatment-resistant depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“a recent systematic review has shown that, although the results of some of the reviewed studies are occasionally inconsistent, there is a general trend indicating that patients with MDD tend to have lower serum levels of BDNF compared to healthy individuals [40].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation
Fujimura, H., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi, J.-I., Sun, B., Altar, C., & Tandon, N. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613072 · Cited by 777 · cited 1×
“Despite that, there were studies that did not differentiate between them or used them interchangeably, which may have affected their results [90].”
ResultPrognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Yoshida, T., Ishikawa, M., Niitsu, T., Nakazato, M., Watanabe, H., Shiraishi, T., Shiina, A., Hashimoto, T., Kanahara, N., Hasegawa, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042676 · Cited by 277
Haile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214 · cited 2×
“…courses of indicated therapies under correct dosages and durations, fails to achieve a reduction of at least 25% in the severity of the symptoms [61]; however, there is significant variability between authors and consensus regarding this definition, its cut-off points and differentiation from…”
BackgroundBrain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses
Kishi, T., Yoshimura, R., Ikuta, T., & Iwata, N. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00308 · Cited by 213
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209 · cited 1×
“In turn, it describes that higher levels of the biomarker are correlated with clinical improvement when using this drug [68].”
BackgroundBocchio-Chiavetto, L., Zanardini, R., Bortolomasi, M., Abate, M., Segala, M., Giacopuzzi, M., Riva, M. A., Marchina, E., Pasqualetti, P., Perez, J., et al. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.04.010 · Cited by 181
Yang, B., Ren, Q., Zhang, J.-C., Chen, Q.-X., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.95 · Cited by 181
Serum BDNF levels before treatment predict SSRI response in depression
Wolkowitz, O. M., Wolf, J., Shelly, W., Rosser, R., Burke, H. M., Lerner, G. K., Reus, V. I., Nelson, J. C., Epel, E. S., & Mellon, S. H. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.013 · Cited by 174
Spronk, D. B., Arns, M., Barnett, K. J., Cooper, N. J., & Gordon, E. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.021 · Cited by 159
Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review
Pinna, M., Manchia, M., Oppo, R., Scano, F., Pillai, G., Loche, A. P., Salis, P., & Minnai, G. P. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.047 · Cited by 156
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152 · cited 1×
“…indicators of less effective treatment without affecting suicidality, while the machine learning algorithm used in that study identified BDNF SNP GG of rs6265, together with the SNPs of HTR2A and PPP3CC in the absence of melancholy, as frequent variations in response to effective treatments [83].”
Cavaleri, D., Moretti, F., Bartoccetti, A., Mauro, S., Crocamo, C., Carrà, G., & Bartoli, F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105159 · Cited by 146 · cited 5×
“However, for Cavaleri, data on other types of antidepressants and studies focused on a single type of antidepressant agent were limited, although he described a significant increase in BDNF with sertraline and non-statistically significant changes with paroxetine, escitalopram and venlafaxine [88].”
InfluentialAllen, A. P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., Scott, L., McLoughlin, D. M., Cryan, J. F., Dinan, T. G., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.033 · Cited by 138
Amare, A. T., Schubert, K. O., & Baune, B. T. (2017) · EPMA Journal · doi:10.1007/s13167-017-0112-8 · Cited by 129
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128 · cited 1×
“However, another randomized study from 2020 identified that there is no evidence of an association between BDNF and the response to treatment with Ayahuasca [35].”
BackgroundBrain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response
Domschke, K., Lawford, B., Laje, G., Berger, K., Young, R., Morris, P., Deckert, J., Arolt, V., McMahon, F. J., & Baune, B. T. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000030 · Cited by 122
Depression: Biological markers and treatment
Nedic Erjavec, G., Sagud, M., Nikolac Perkovic, M., Svob Strac, D., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 119
Rong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114 · cited 1×
“…to the drug, evidenced in a 2012 investigation in which the scores obtained with the HAM-D presented significantly smaller changes among those who carried Met compared with those who carried Val, which suggests a greater response to intravenous Ketamine among Val/Val BDNF carriers in rs6265e [60].”
Suggested Biomarkers for Major Depressive Disorder
Hacimusalar, Y., & Esel, E. (2017) · Noro Psikiyatri Arsivi · doi:10.5152/npa.2017.19482 · Cited by 113
5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression
Bocchio‐Chiavetto, L., Miniussi, C., Zanardini, R., Gazzoli, A., Bignotti, S., Specchia, C., & Gennarelli, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.04.005 · Cited by 111
Rybakowski, J. K., Permoda‐Osip, A., Skibinska, M., Adamski, R., & Bartkowska‐Sniatkowska, A. (2013) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2271 · Cited by 93
Carboni, L., McCarthy, D. J., Delafont, B., Filosi, M., Ivanchenko, E., Ratti, E., Learned, S. M., Alexander, R., & Domenici, E. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0521-7 · Cited by 89
Brunoni, A. R., Kemp, A. H., Shiozawa, P., Cordeiro, Q., Valiengo, L. D. C. L., Goulart, A. C., Coprerski, B., Lotufo, P. A., Brunoni, D., Perez, A. B. A., et al. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.009 · Cited by 87
Assessing BDNF as a mediator of the effects of exercise on depression
Szuhany, K. L., & Otto, M. W. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.02.003 · Cited by 85
The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review
Webb, L. M., Phillips, K. E., Ho, M. C., Veldic, M., & Blacker, C. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030826 · Cited by 84 · cited 1×
“Likewise, in this same investigation, it was shown that hypomethylation of the promoter prior to treatment is associated with worse responses, while greater methylation of the BDNF promoter after treatment is associated with remission of depression [56].”
BackgroundTadić, A., Wagner, S., Schlicht, K. F., Peetz, D., Borysenko, L., Dreimüller, N., Hiemke, C., & Lieb, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.011 · Cited by 82
Fabbri, C., Hosak, L., Mössner, R., Giegling, I., Mandelli, L., Bellivier, F., Claes, S., Collier, D. A., Corrales, A., Delisi, L. E., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1208843 · Cited by 81
Yoshida, K., Higuchi, H., Kamata, M., Takahashi, H., Inoue, K., Suzuki, T., Itoh, K., & Ozaki, N. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072192 · Cited by 80
Lisoway, A. J., Zai, C. C. H., Tiwari, A. K., & Kennedy, J. L. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.12.071 · Cited by 80
Advances in Biomarkers of Major Depressive Disorder
Huang, T., & Lin, C.-C. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.11.003 · Cited by 79
Silverstein, W. K., Noda, Y., Barr, M. S., Vila-Rodriguez, F., Rajji, T. K., Fitzgerald, P. B., Downar, J., Mulsant, B. H., Vigod, S., Daskalakis, Z. J., et al. (2015) · Depression and Anxiety · doi:10.1002/da.22424 · Cited by 76
Mikoteit, T., Beck, J., Eckert, A., Hemmeter, U., Brand, S., Bischof, R., Holsboer‐Trachsler, E., & Delini‐Stula, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3475-8 · Cited by 72
Focus on ECT seizure quality: serum BDNF as a peripheral biomarker in depressed patients
Bumb, J. M., Aksay, S. S., Janke, C., Kranaster, L., Geisel, O., Gass, P., Hellweg, R., & Sartorius, A. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0543-3 · Cited by 72
Li, Z., Zhang, Y., Wang, Z., Chen, J., Fan, J., Guan, Y., Zhang, C., Yuan, C., Hong, W., Wang, Y., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.10.003 · Cited by 63
Wang, P., Zhang, C., Lv, Q., Bao, C., Sun, H., Ma, G., Fang, Y., Yi, Z., & Cai, W. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2463-z · Cited by 58
Tatham, E. L., Hall, G. B. C., Clark, D., Foster, J. A., & Ramasubbu, R. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0702-9 · Cited by 57
Colle, R., Gressier, F., Verstuyft, C., Deflesselle, E., Lépine, J.-P., Ferreri, F., Hardy, P., Guilloux, J.-P., Petit, A.-C., Fève, B., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.013 · Cited by 55
Lieb, K., Dreimüller, N., Wagner, S., Schlicht, K., Falter, T., Neyazi, A., Müller-Engling, L., Bleich, S., Tadić, A., & Frieling, H. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00511 · Cited by 54
Lanctôt, K. L., Rapoport, M. J., Chan, F., Rajaram, R. D., Strauss, J., Sicard, T., McCullagh, S., Feinstein, A., Kiss, A., Kennedy, J. L., et al. (2010) · Brain Injury · doi:10.3109/02699051003789229 · Cited by 54
Yoshimura, R., Ikenouchi, A., Hori, H., Umene‐Nakano, W., Katsuki, A., Hayashi, K., Ueda, N., & Nakamura, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.003 · Cited by 54
Brunoni, A. R., Padberg, F., Vieira, E. L. M., Teixeira, A. L., Carvalho, A. F., Lotufo, P. A., Gattaz, W. F., & Benseñor, I. M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.003 · Cited by 53
Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment‐resistant psychiatric disorders
Valiulienė, G., Valiulis, V., Dapšys, K., Vitkevičienė, A., Gerulskis, G., Navakauskienė, R., & Germanavičius, A. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15232 · Cited by 52
Beuzon, G., Timour, Q., & Saoud, M. (2016) · L Encéphale · doi:10.1016/j.encep.2016.11.002 · Cited by 51
Murphy, G. M., Sarginson, J. E., Ryan, H. S., O’Hara, R., Schatzberg, A. F., & Lazzeroni, L. C. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328360b175 · Cited by 50
Neurotrophic factors in depression in response to treatment
Buttenschøn, H. N., Foldager, L., Elfving, B., Poulsen, P. H. P., Uher, R., & Mors, O. N. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.027 · Cited by 48
Increased levels of plasma IL-1b and BDNF can predict resistant depression patients
Uint, L., Bastos, G. M., Thurow, H. S., Borges, J. B., Hirata, T. D. C., França, J. Í. D., Hirata, M. H., & Sousa, A. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.3.361 · Cited by 48
Maffioletti, E., Silva, R. C., Bortolomasi, M., Baune, B. T., Gennarelli, M., & Minelli, A. (2021) · Brain Sciences · doi:10.3390/brainsci11091120 · Cited by 45
Huuhka, K., Sami, A., Huuhka, M., Esa, L., Rontu, R., Mattila, K. J., & Lehtimäki, T. J. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0679-x · Cited by 42
Marshe, V. S., Islam, F., Maciukiewicz, M., Bousman, C., Eyre, H. A., Lavretsky, H., Mulsant, B. H., Reynolds, C. F., Lenze, E. J., & Müller, D. J. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.01.007 · Cited by 42
Rojas, P. S., Fritsch, R., Rojas, R., Jara, P., & Fiedler, J. L. (2011) · Psychiatry Research · doi:10.1016/j.psychres.2011.04.032 · Cited by 41
Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
Dvojkovic, A., Perković, M. N., Šagud, M., Erjavec, G. N., Peleš, A. M., Štrac, D. Š., Ćusa, B. V., Tudor, L., Kušević, Z., Konjevod, M., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110016 · Cited by 39
Ghosh, R., Gupta, R., Bhatia, M. S., Tripathi, A. K., & Gupta, L. K. (2015) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2015.10.006 · Cited by 37
Early changes of serum BDNF and SSRI response in adolescents with major depressive disorder
Lee, J., Lee, K. H., Kim, S. H., Han, J. Y., Hong, S.-B., Cho, S.-C., Kim, J.-W., & Brent, D. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.045 · Cited by 37
Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome
van Zutphen, E. M., Rhebergen, D., van Exel, E. R., Oudega, M. L., Bouckaert, F., Sienaert, P. A., Vandenbulcke, M., Stek, M. L., & Dols, A. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0491-9 · Cited by 37
Krstić, J., Buzadžić, I., Milanović, S. D., Ilić, N. V., Pajić, S., & Ilić, T. V. (2014) · The Journal of ECT · doi:10.1097/yct.0000000000000099 · Cited by 37
Maffioletti, E., Gennarelli, M., Gainelli, G., Bocchio‐Chiavetto, L., Bortolomasi, M., & Minelli, A. (2019) · Journal of Ect · doi:10.1097/yct.0000000000000583 · Cited by 36
Francazio (2015) · doi:10.1016/j.psychres.2015.04.009 · Cited by 35 · cited 1×
“A 2015 study that subjected 21 TRD patients to ECT also failed to identify significant correlations [74].”
Lin, C.-H., Chen, M.-C., Lee, W.-K., Chen, C.-C., Huang, C.-H., & Lane, H.-Y. (2013) · Neuropsychobiology · doi:10.1159/000352013 · Cited by 35
Liu, X., Li, P., Ma, X., Zhang, J., Sun, X., Luo, X., & Zhang, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.041 · Cited by 34
Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression
Hong, W., Fan, J., Yuan, C., Zhang, C., Hu, Y., Peng, D., Wang, Y., Huang, J., Li, Z., Yu, S., et al. (2014) · NeuroReport · doi:10.1097/wnr.0000000000000165 · Cited by 34
Chen, M.-H., Kao, C.-F., Tsai, S.-J., Li, C.-T., Lin, W.-C., Hong, C.-J., Bai, Y.-M., Tu, P.-C., & Su, T.-P. (2021) · Genomics · doi:10.1016/j.ygeno.2020.12.030 · Cited by 33
Palm, U., Fintescu, Z., Obermeier, M., Schiller, C., Reisinger, E., Keeser, D., Pogarell, O. M., Bondy, B., Zill, P., & Padberg, F. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.03.015 · Cited by 33
EPA and DHA as markers of nutraceutical treatment response in major depressive disorder
van der Burg, K. P., Cribb, L., Firth, J., Karmacoska, D., Mischoulon, D., Byrne, G. J., Bousman, C., Stough, C. K. K., Murphy, J., Oliver, G., et al. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02090-6 · Cited by 33
Lu, H., Chan, S. S. M., Ma, S., Lin, C., Mok, V., Shi, L., Wang, D., Mak, A. D. P., & LAM, L. C. W. (2022) · Human Brain Mapping · doi:10.1002/hbm.26032 · Cited by 31
BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine
Ninan, P. T., Shelton, R. C., Bao, W., & Guico‐Pabia, C. J. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.016 · Cited by 29
Eletroconvulsoterapia na depressão maior: aspectos atuais
Antunes, P., Rosa, M. A., Belmonte-de-Abreu, P. S., Lobato, M. I. R., & Fleck, M. P. D. A. (2009) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462009000500005 · Cited by 29
Bruijniks, S. J. E., van Grootheest, G., Cuijpers, P. J., de Kluiver, H., Vinkers, C. H., Peeters, F. P. M. L., Penninx, B. W. J. H., Teunissen, C. E., & Huibers, M. J. H. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.07.045 · Cited by 28
Sorri, A., Järventausta, K., Kampman, O., Lehtimäki, K. A., Björkqvist, M., Tuohimaa, K., Hämäläinen, M., Moilanen, E., & Leinonen, E. V. J. (2018) · Brain and Behavior · doi:10.1002/brb3.1101 · Cited by 28
Blood-based biomarkers predicting response to antidepressants
Busch, Y., & Menke, A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-018-1844-x · Cited by 27
Dimitriadis, M., van den Brink, R. H. S., Comijs, H. C., & Voshaar, R. C. O. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.02.003 · Cited by 25
Šagud, M., Perković, M. N., Dvojkovic, A., Jakšić, N., Vuksan‐Ćusa, B., Živković, M., Kušević, Z., Mihaljević-Peleš, A., & Pivac, N. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05790-2 · Cited by 22
Pathak, P., Mehra, A., Ram, S., Pal, A., & Grover, S. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113931 · Cited by 22
Xiao, L., Correll, C. U., Feng, L., Xiang, Y., Feng, Y., Hu, C., Li, R., & Wang, G. (2018) · CNS Spectrums · doi:10.1017/s1092852917000670 · Cited by 22
Kim, K., Jang, E. H., Kim, A. Y., Fava, M., Mischoulon, D., Papakostas, G. I., Kim, H., Na, E. J., Yu, H. Y., & Jeon, H. J. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152140 · Cited by 21
Rahman, M. S., Millischer, V., Zeebari, Z., Forsell, Y., & Lavebratt, C. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.05.007 · Cited by 20
Bareš, M., Novák, T., Brunovský, M., Kopeček, M., & Höschl, C. (2016) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000574 · Cited by 20
Yoshimura, R., Umene‐Nakano, W., Ueda, N., Ikenouchi, A., Hori, H., & Nakamura, J. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.979 · Cited by 20
Gkesoglou, T., Bargiota, S. I., Iordanidou, E., Vasiliadis, M., Bozikas, V., & Agorastos, A. (2022) · Brain Sciences · doi:10.3390/brainsci12070940 · Cited by 20
Viikki, M., Järventausta, K., Leinonen, E. V. J., Huuhka, M., Mononen, N., Lehtimäki, T. J., & Kampman, O. (2013) · Psychiatric Genetics · doi:10.1097/ypg.0b013e328360c894 · Cited by 20
Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs
Yoshimura, R., Kishi, T., Hori, H., Katsuki, A., Ikenouchi, A., Umene‐Nakano, W., Atake, K., Iwata, N., & Nakamura, J. (2014) · Psychiatry Investigation · doi:10.4306/pi.2014.11.1.84 · Cited by 19
Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
Psomiades, M., Mondino, M., Galvão, F., Mandairon, N., Nourredine, M., Suaud‐Chagny, M., & Brunelin, J. (2022) · Brain Sciences · doi:10.3390/brainsci12020126 · Cited by 17
BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression
Schosser, A., Fischer-Hansal, D., Swoboda, M. M. M., Ludwig, B., Carlberg, L., Swoboda, P., Kienesberger, K., Bernegger, A., Fuxjäger, M., Zotter, M., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.03.005 · Cited by 17
Ramesh, V., Venkatesan, V., Chellathai, D., & Silamban, S. (2020) · Neuropsychobiology · doi:10.1159/000507371 · Cited by 16
Kang, M. J. Y., & Vázquez, G. H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.047 · Cited by 15
Martin, D. M., McClintock, S. M., Aaronson, S. T., Alonzo, A., Husain, M. M., Lisanby, S. H., McDonald, W. M., Mohan, A., Nikolin, S., O’Reardon, J. P., et al. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.08.011 · Cited by 13
Pharmacogenetic studies: a tool to improve antidepressant therapy
Ramos, M., Berrogain, C., Concha, J., Lomba, L., García, C. B., & Ribate, M. P. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0019 · Cited by 12
Convergent neurobiological predictors of mood and anxiety symptoms and treatment response
Jabbi, M., & Nemeroff, C. B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1620604 · Cited by 10
Du, D., Tang, Q., Han, Q., Zhang, J., Liang, X., Tan, Y., Liu, K., & Xiang, B. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0037 · Cited by 8
Serum BDNF Levels are Not Associated with the Antidepressant Effects of Nonconvulsive Electrotherapy
Zheng, W., Jiang, M., He, H., Li, R., Li, Q., Zhang, C., Zhou, S., Yan, S., Ning, Y., & Huang, X. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s256278 · Cited by 8
Cited by
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
Han, H., Yao, J., Wu, J., Mao, S., Pan, H., Qv, L., Zhu, G., Ren, J., Yu, Y., Xuan, F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03044-7 · Cited by 51
Exploring depression in adults over a decade: a review of longitudinal studies
de Sousa, R. D., Zagalo, D. M., Costa, T., de Almeida, J. M. C., Canhão, H., & Rodrigues, A. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06828-x · Cited by 44
“Additionally, a systematic review highlighted that early increases in BDNF levels after treatment initiation could indicate a positive response, underscoring the potential of BDNF as a predictor of treatment response in MDD [81].”
Liberona, A., Jones, N., Zúñiga, K., Candia, V. A. G., Zelada, M. I., Hernán Silva, I., & Nieto, R. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011204 · Cited by 36
Self-citation
Metadata
- Authors
- Zelada, M. I., Garrido, V., Liberona, A., Jones, N., Zúñiga, K., Silva, H., & Nieto, R. R.
- Affiliations
- University of Chile (CL)
- Clínica Psiquiátrica Universitaria, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago 8380453, Chile
- Hospital Clínico de la Universidad de Chile (CL)
- Corresponding author
- Nieto, Rodrigo R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-30
- Volume
- 24
- Issue
- 19
- Pages
- 14810
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10572866
- OpenAlex
- W4387230599
- Cited by
- 60
- References
- 92
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 19
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Universidad de Chile (submittedVersion, cc-by-nc-nd)
- Funders
- Agencia Nacional de Investigación y Desarrollo (ANID) (11231216)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- brain-derived neurotrophic factor, major depressive disorder, treatment response prediction, biomarkers, BDNF polymorphism, pharmacotherapy, non-pharmacological treatment, treatment-resistant depression
- MeSH terms
- Depressive Disorder, Major, Major Depressive Disorder, Humans, Polymorphism, Genetic, Biomarkers, Brain-Derived Neurotrophic Factor, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.